ArticleFrontiers in medicine2026
Family history of cancer and risk of lung cancer: a retrospective cohort study in a Chinese population.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Family history of cancer is an established risk factor for lung cancer, but its association with the probability of malignancy among patients evaluated for pulmonary nodules-rather than with population-level lung cancer incidence-remains poorly characterized in Chinese populations. Methods: We conducted a retrospective cohort study of 3,850 consecutive patients evaluated for pulmonary nodules at a tertiary teaching hospital between January 2018 and December 2021, of whom 1,257 (32.6%) underwent surgical resection or biopsy. Family history of lung and non-lung cancer in first- and second-degree relatives was self-reported at admission. Lung cancer was confirmed histopathologically. Sequential multivariable logistic regression was performed: Model 1 included clinical variables only, and Model 2 additionally included radiological features. Results: Among 3,850 patients, 1,158 (30.1%) had pathology-confirmed lung cancer (95.3% adenocarcinoma; 92.2% stage IA). The 2,692 controls comprised 99 patients with pathology-confirmed benign lesions and 2,593 patients managed with imaging surveillance in whom no malignant pathology was recorded. First-degree family history of lung cancer (present in 32.3% of the cohort) was not associated with malignancy in univariate analysis (OR 0.94, 95% CI 0.81-1.09, Conclusion: In this selected cohort of patients evaluated for pulmonary nodules, family history was not positively associated with malignancy, and the inverse adjusted associations are most plausibly explained by referral- and surveillance-related selection rather than biological protection. Radiological assessment should remain the primary basis for pulmonary nodule management. Family history may be considered during nodule evaluation, but its independent contribution should be validated in prospective cohorts with standardized screening and referral procedures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.